Imre Pavo

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes
    Imre Pavo
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46201, USA
    J Clin Endocrinol Metab 88:1637-45. 2003
  2. ncbi Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis
    Peiqi Chen
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Bone Miner Res 22:1173-80. 2007
  3. ncbi Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial
    Bjorn Andersson
    University of Goteborg, S 413 45 Goteborg, Sweden
    J Clin Endocrinol Metab 87:122-8. 2002
  4. ncbi Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study
    Olof Johnell
    Department of Orthopaedics, , Malm, Sweden
    J Bone Miner Res 19:764-72. 2004
  5. ncbi Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    J Bone Miner Res 19:745-51. 2004
  6. ncbi Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial
    John A Kanis
    WHO Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Bone 33:293-300. 2003
  7. ncbi Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, University of Liege, Liege, Belgium
    Osteoporos Int 14:741-9. 2003
  8. ncbi Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels
    Brigitte Uebelhart
    Service of Bone Diseases WHO Collaborating Center for Osteoporosis Prevention, Department of Rehabilitation and Geriatrics, University Hospital, Geneva 14 CH 1211, Switzerland
    J Bone Miner Res 19:1518-24. 2004
  9. ncbi Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy
    Harald Dobnig
    Department of Internal Medicine, Division of Endocrinology, Medical University, Auenbruggerplatz 15, A 8036 Graz, Austria
    J Clin Endocrinol Metab 90:3970-7. 2005
  10. ncbi Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1
    Patrick Neven
    Department of Gynaecological Oncology and Multidisciplinary Breast Centre, UZ Gasthuisberg, Leuven, Belgium
    Maturitas 52:87-101. 2005

Collaborators

Detail Information

Publications13

  1. ncbi Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes
    Imre Pavo
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46201, USA
    J Clin Endocrinol Metab 88:1637-45. 2003
    ....
  2. ncbi Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis
    Peiqi Chen
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Bone Miner Res 22:1173-80. 2007
    ..Therefore, improvements in trabecular bone microarchitecture may be one of the mechanisms to explain how BMD increases improve bone strength during teriparatide treatment...
  3. ncbi Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial
    Bjorn Andersson
    University of Goteborg, S 413 45 Goteborg, Sweden
    J Clin Endocrinol Metab 87:122-8. 2002
    ....
  4. ncbi Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study
    Olof Johnell
    Department of Orthopaedics, , Malm, Sweden
    J Bone Miner Res 19:764-72. 2004
    ..006) and lower LS BMD values (p = 0.008) at baseline. These data suggest that the efficacy of raloxifene in reducing vertebral fractures is largely independent of the presence of clinical risk factors for osteoporotic fractures...
  5. ncbi Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    J Bone Miner Res 19:745-51. 2004
    ..Conversely, previous alendronate treatment reduced the bone marker and BMD response...
  6. ncbi Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial
    John A Kanis
    WHO Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Bone 33:293-300. 2003
    ....
  7. ncbi Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, University of Liege, Liege, Belgium
    Osteoporos Int 14:741-9. 2003
    ....
  8. ncbi Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels
    Brigitte Uebelhart
    Service of Bone Diseases WHO Collaborating Center for Osteoporosis Prevention, Department of Rehabilitation and Geriatrics, University Hospital, Geneva 14 CH 1211, Switzerland
    J Bone Miner Res 19:1518-24. 2004
    ..In healthy middle-aged men, raloxifene treatment was associated with increased serum estradiol and decreased biochemical markers of bone turnover in subjects with estradiol levels below a threshold of 101.8 pM...
  9. ncbi Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy
    Harald Dobnig
    Department of Internal Medicine, Division of Endocrinology, Medical University, Auenbruggerplatz 15, A 8036 Graz, Austria
    J Clin Endocrinol Metab 90:3970-7. 2005
    ..Biochemical markers of bone turnover may reflect bone structure during anabolic treatment...
  10. ncbi Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1
    Patrick Neven
    Department of Gynaecological Oncology and Multidisciplinary Breast Centre, UZ Gasthuisberg, Leuven, Belgium
    Maturitas 52:87-101. 2005
    ....
  11. ncbi The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis
    Dana Michalska
    Third Department of Internal Medicine, Charles University, Faculty of Medicine, U Nemocnice 1, 128 00 Prague, Czech Republic
    J Clin Endocrinol Metab 91:870-7. 2006
    ....
  12. ncbi Mood effect of raloxifene in postmenopausal women
    Natalia B Jarkova
    Mental Health Research Center, Russian Academy of Medical Sciences, Kashirskoye Shosse 34, Moscow, Russia
    Maturitas 42:71-5. 2002
    ..Larger, long-term studies are required to evaluate a possible mood improvement effect of raloxifene...
  13. ncbi Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis
    Jan J Stepan
    Institute of Rheumatology, Charles University, Faculty of Medicine, Prague, Czech Republic
    Bone 41:378-85. 2007
    ..04 for Cr.Dn and P=0.03 for Cr.S.Dn). We conclude that increased microdamage accumulation may occur in low BMD patients treated with alendronate...